FDA vouchers are normally a coveted prize for biopharma companies, but a surprise rejection for Disc Medicine’s rare disease drug has biopharma reconsidering.
MedPage Today on MSNOpinion
FDA expert panels raise legal, credibility questions
Handpicked panels don't fulfill federal requirements, group argues ...
Pharmaceutical Technology on MSN
FDA’s commissioner vouchers prompt questions about award process
Despite the FDA’s CNPV scheme generating high interest, the process around how voucher awards are prioritised remains unclear ...
At the highest levels of the FDA, questions remain about which officials have the legal authority to sign off on drugs cleared under the Commissioner’s National Priority Voucher program, which ...
WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Donald Trump’s administration is causing alarm across the ...
WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Donald Trump’s administration is causing alarm across the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results